<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631862</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2018-5</org_study_id>
    <nct_id>NCT03631862</nct_id>
  </id_info>
  <brief_title>Treatment of Newly Diagnosed Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With
      CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly
      diagnosed peripheral T-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot
      be treated successfully with the conventional CHOP regimen. Apatinib is a small-molecule
      multitargeted tyrosine kinase inhibitor. The investigators have been proceeding this trial to
      evaluate the efficacy and safety of the Apatinib Combined With CHOP Regimen(cyclophosphamide,
      vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell
      lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RR</measure>
    <time_frame>every 6 weeks, up to completion of treatment (approximately 18 weeks)</time_frame>
    <description>Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to the date of death (approximately 5 years)</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Newly Diagnosed Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Apatinib combined with CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.</description>
    <arm_group_label>Apatinib combined with CHOP regimen</arm_group_label>
    <other_name>Apatinib mesylate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP Regimen</intervention_name>
    <description>CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)</description>
    <arm_group_label>Apatinib combined with CHOP regimen</arm_group_label>
    <arm_group_label>CHOP regimen</arm_group_label>
    <other_name>CHOP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range 14-70 years old; ECOG performance status 0-2.

          -  Estimated survival time &gt; 6 months.

          -  Histological confirmed Peripherial T-cell lymphoma.

          -  Have taken no treatment.

          -  None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L,
             platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤
             1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is
             normal.

          -  At least one measurable lesion.

          -  None of other serious diseases, cardiopulmonary function is normal.

          -  Pregnancy test of women at reproductive age must be negative.

          -  Patients could be followed up.

          -  None of other relative treatments including the traditional Chinese medicine,
             immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic
             treatments.

          -  Volunteers who signed informed consent.

        Exclusion Criteria:

          -  Patients with contraindications (active bleeding, ulcers, intestinal perforation,
             intestinal obstruction, 30 days after major surgery, hypertension uncontrollable
             drugs, grade III-IV cardiac insufficiency, severe liver and kidney dysfunction);

          -  Abnormal coagulation (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 seconds or APTT &gt;
             1.5 ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy；

          -  Urine routine indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0
             g;

          -  Disagreement on blood sample collection.

          -  Patients allergic of any of drug in this regimen or with metabolic disorder.

          -  Pregnant or lactating women.

          -  Serious medical illness likely to interfere with participation.

          -  Serious infection.

          -  Primitive or secondary tumors of central nervous system.

          -  Chemotherapy or radiotherapy contraindication.

          -  The evidence of CNS metastasis.

          -  History of peripheral nervous disorder or dysphrenia.

          -  Patients participating in other clinical trials.

          -  Patients taking other antitumor drugs.

          -  Patients estimated to be unsuitable by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>China, Henan Oncology Department of The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Department of The First Affilliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 12, 2018</last_update_submitted>
  <last_update_submitted_qc>August 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>peripheral T-cell lymphoma</keyword>
  <keyword>Apatinib</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>RR</keyword>
  <keyword>PFS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

